George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Another official update by the end of the month would be great. Let’s have that rig info and projected spud date. 2023 could be an exceptional year, but then again it needs to be!
I'll tell you why. Most LTH'ers invested in this many years ago, they did their due dilligence, found out what SAR was all about and believed in the final outcome, that hasn't changed and is part of the journey. A large number brought in at a very low level and are in profit, they could have sold and many have managed their portfolio well over the ups and downs. The moral of the story is this, be patient! its only the greedy wombles that are panicking as they brought high and are currently out of pocket, there may also be some geniune holders that are under water but only you can decide.
GLA
FTC, on days like these, it certainly focuses the mind and people re-assess their position, much to the glee of the MM's. SAR still has a lot to offer and when you look at the overall timeline a delay is not unexpected. The MHRA will be meticulous and look for any reason to question an application, it's their job, just imagine the implications if they didn't!
For me, nothing has changed and I raided the piggy bank this morning like many others, at great opportunity that I didn't expect. Clarification will follow as soon as they know what is required, it will probably be in the form of a CTA approval RNS.
GLA
From let’s manipulate the market brigade! Excellent opportunity to average down for some, if they have the funds. We all knew that the delay was unusual, but as stated that was with the MHRA on a technicality. SAR think that they provided everything that they needed and until the MHRA provide the feed back on the detail required, there will be a delay. Outside of this everything remains the same. Don’t be fooled by this manipulation and hold on, the SP will recover in no time.
GLA
HBD, I think that it is now clear that something is going on, outside of the normal CTA process.
I don’t doubt that 1801 is going into the clinic. I also believe that the BOD are busy trying to plan the next steps with 737 and 1802, they certainly have a lot of plates spinning in the background, and that’s without potential licensing deals, JV’s or suitors. Interesting times that’s for sure!
Actually no Sneckie, just look at the raft of nonsense over the last couple of days. The board is a lot nicer place without them. LTH’s of SAR will of course be frustrated but are here for the final countdown to successful trials, if only one out of the three drugs succeed, it will be enough for many. A potential blockbuster! Those that regularly post their research and provide facts, coupled with the information provided by the BOD have no doubt about the future. Stay positive and hold.
Personally I’m glad that this protracted saga with Sierra has ended. They had no intention of taking that next step forward with 737, hence the stalling and dithering by Dilly and co. 737 should have been treating patients by now, and that is the major disappointment (how many lives lost?). Who knows what politics got in the way but that now lies in the past. Now there is a great opportunity if CRT and Sareum can progress this relatively quickly, in that respect nothing has changed. We still have 3 compounds that can make a difference to many thousands of people. Come on Tim and the team, just do it??
I’m sure there were some posts here last week, where have the gone?
They weren’t ver complimentary which is no surprise really!
Even with the ATOM spinoff many investors are still underwater and a long way from break even. This is the truth for PL to understand and resolve.
If GSK do take on 737 and develop it further, it will provide SAR with a valuable source of income. This income would easily fund current and future products. At this point the big Pharmas have a conundrum to solve, buy the lot or pay much more over the longer term, albeit in smaller chunks.
GLA
Stay positive and don’t sell out cheaply.